An observational study in Essential Hypertension and Primary Hypercholesterolemia, sponsored by Boryung Pharmaceutical Co., Ltd. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Boryung Pharmaceutical Co., Ltd · Observational
This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or the combination of fimasartan, atorvastatin, and ezetimibe.
478 studies on the registry are indexed under Essential Hypertension; 74 are open to participants now.
This study's planned enrollment of 12,700 is above the median of 702 across 70 observational studies indexed under Essential Hypertension.
Browse Essential Hypertension studies →Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with essential hypertension and primary hypercholesterolemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The proportion of patients with positive urine dipstick albuminuria
Time frame: Week 12
Change in UACR from baseline to Weeks 12 and 24
UACR is defined as the urine albumin-to-creatinine ratio
Time frame: Week 12, Week 24
Proportion of participants achieving a ≥30% reduction in UACR from baseline at Weeks 12 and 24
UACR is defined as the urine albumin-to-creatinine ratio
Time frame: Week 12, Week 24
Change in UPCR from baseline to Weeks 12 and 24
UPCR is defined as the urine protein-to-creatinine ratio
Time frame: Week 12, Week 24
Proportion of participants achieving a ≥30% reduction in UPCR from baseline at Weeks 12 and 24
UPCR is defined as the urine protein-to-creatinine ratio
Time frame: Week 12, Week 24
Change in eGFR from baseline to Weeks 12 and 24
eGFR is defined as the estimated glomerular filtration rate
Time frame: Week 12, Week 24
Proportion of participants with a ≥50% decline in eGFR from baseline at Weeks 12 and 24
eGFR is defined as the estimated glomerular filtration rate
Time frame: Week 12, Week 24
Change in blood pressure from baseline at Weeks 12 and 24
Time frame: Week 12, Week 24
Proportion of participants achieving the target blood pressure at Weeks 12 and 24
Time frame: Week 12, Week 24
Change in lipid profile (TC, HDL-C, TG, and LDL-C) from baseline at Weeks 12 and 24
Lipid proflie was defined that Total cholesterol (TC); High-density lipoprotein cholesterol (HDL-C);Triglycerides (TG); Low-density lipoprotein cholesterol (LDL-C)
Time frame: Week 12, Week 24
Proportion of participants achieving the target LDL-C level at Weeks 12 and 24
Time frame: Week 12, Week 24
Proportion of participants achieving both the target blood pressure and target LDL-C level at Weeks 12 and 24
Time frame: Week 12, Week 24
No study locations are listed for this record.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boryung Pharmaceutical Co., Ltd →